Skip to content
DataLookout
Menu

SENSTROKENCT07510919

CGM in Acute Ischemic Stroke

StatusRecruiting
PhaseNot applicable
SponsorIsala
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 6 more changesShow less
    • Primary endpoints: details revised at 1 of 1 entry
    • Eligibility criteria expanded, about 5 words
    • Study sites: 0 to 2
    • Start date changed from estimate of Apr 2026 to Apr 21, 2026
    • Secondary endpoints: details revised at 5 of 9 entries
    • Collaborators expanded, about 3 words
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Time spent in hyperglycemia (>10 mmol/L)
Timeframe: During the first 72 hours of hospitalization

Secondary (9)

Duration of hyperlgycemic episodes (>10 mmol/L)
Duration of hypoglycemic episodes (<3.9 mmol/L)
Time in normoglycemia (3.9-10.0 mmol/L)
Time in hypoglycemia (<3.9 mmol/L)
In-hospital complications
Show 4 moreShow less
Neurological recovery
Good functional outcome
Health-related quality of life
All-cause mortality

Arms and interventions

CGM-guided glucose managementExperimental

Participants receive glucose monitoring using a continuous glucose monitoring (CGM) system (FreeStyle Libre 2). Glucose management during hospitalization is guided by CGM measurements and used for treatment decisions according to the hospital glucose management protocol.

POCT-guided glucose managementActive comparator

Participants receive standard glucose monitoring using intermittent point-of-care testing (POCT) with capillary finger-prick measurements. Glucose management during hospitalization follows the hospital glucose management protocol based on POCT values. A blinded continuous glucose monitoring sensor (FreeStyle Libre Pro iQ) is placed for data collection purposes only. CGM data are not available to the clinical team and are not used for treatment decisions.

Devices: Continuous Glucose Monitoring

Diagnostic tests: Point-of-Care Testing

Sites

2 sites in 1 country